Director/PDMR Shareholding
20/10/2025 17:54
RNS Number : 1047E Oxford Biomedica PLC 20 October 2025 PDMR Dealing Oxford, UK - 20 October 2025: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that Kyriacos Mitrophanous, Chief Innovation Officer of the Company, exercised 26,210 LTIP options at nil exercise price on 20 October 2025 and disposed of 26,210 shares at an average price of £5.758376 per share on 20 October 2025. The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the transaction.
| 1. | Details of thePerson Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
| a) | Name | Kyriacos Mitrophanous | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Person Discharging Managerial Responsibility | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Date of the transaction | 2025-10-20 | ||||
| b) | Description of the financial instrument | Options over Ordinary Shares of 50 pence each | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Exercise of LTIP Options at nil exercise price | ||||
| e) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 26,210 £0.00 £0.00 | ||||
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
| a) | Name | Kyriacos Mitrophanous | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Person Discharging Managerial Responsibility | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Name | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Date of the transaction | 2025-10-20 | ||||
| b) | Description of the financial instrument | Ordinary Shares of 50 pence each | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of transaction | Sale of shares | ||||
| e) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 26,210 £5.758376 £150,927.03 | ||||